By Dean Seal
Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share.
The stock was up 14% at $2.48 in premarket trading. Shares had fallen 31% year to date when the market closed Thursday.
The Los Angeles-based late-stage biopharma company said Friday morning that Concentra's all-cash proposal includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property.
The offer comes after Acelyrin agreed earlier this month to merge with Alumis in an all-stock deal that is expected to close in the second quarter.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 21, 2025 09:16 ET (14:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.